Corteva (CTVA) Q4 2025 earnings review
Strong Year, Messy Quarter, Big Breakup Ahead
Corteva capped a strong 2025 with a noisy fourth quarter. While full-year Operating EBITDA surged 14% to $3.85B and EPS jumped 30%, Q4 itself was a miss: Net Sales fell 2% and Operating EBITDA dropped 15% due to seasonal volume shifts and pricing pressure in Latin America. The real headline is strategic: the company settled massive litigation with Bayer (clearing the path to royalty neutrality) and is on track to split into two separate public companies in H2 2026. Guidance for 2026 predicts continued but decelerating growth.
🐂 Bull Case
Despite a 2% sales dip in Q4, Seed Operating EBITDA surged 33%, expanding margins by 190bps. The segment is benefitting from deflation and productivity, proving it can grow profits even when top-line volume shifts between quarters.
Free Cash Flow jumped 69% YoY to $2.9 billion for FY25. This massive cash generation funded $1.5 billion in shareholder returns and provides the war chest for the $610M Bayer settlement without stressing the balance sheet.
🐻 Bear Case
The Crop Protection segment is struggling with pricing power, particularly in Latin America. Q4 segment EBITDA fell 22% with margins collapsing 435bps. Management cites 'competitive pricing dynamics,' a polite way of saying they are losing leverage.
Q4 volume dropped 5% due to 'seasonal timing shifts' into Q1 2026 and Q3 2025. While management explains this away, the volatility makes quarterly predictability difficult and raises questions about true underlying demand versus channel stuffing.
⚖️ Verdict: 🟢
Bullish. Ignore the Q4 noise; the full-year execution was stellar (+30% EPS). The Bayer settlement removes a major overhang, and the separation catalyst in 2026 unlocks value. The divergence between strong Seed performance and weak Crop Protection confirms why splitting the company makes sense.
Key Themes
Seed Profitability Breakout
The Seed segment is the star performer. In Q4, despite revenue falling 2% due to timing shifts, Operating EBITDA climbed 33% ($124M vs $93M). Cost benefits and deflation are flowing directly to the bottom line. This segment is carrying the company while Crop Protection struggles.
Crop Protection Margin Compression
Crop Protection (CP) is flashing red. Q4 EBITDA margin compressed by ~435 basis points YoY. While volume only fell 2%, the inability to hold price in Latin America combined with higher compensation and R&D costs crushed profitability. The segment is facing a 'competitive pricing environment' that isn't abating quickly.
Bayer Settlement & Royalty Neutrality
Corteva agreed to pay Bayer $610M to resolve all litigation. While a large cash outflow for Q1 2026, this accelerates 'royalty neutrality' to 2026—two years ahead of schedule. It also opens the door to out-licensing triple-stack corn traits by 2027. This turns a legal headache into a commercial opportunity.
Biologicals & New Products
Amidst general CP weakness, the bright spot remains adoption of new tech. Crop Protection volumes in FY25 grew 5%, driven specifically by 'demand for new products and biologicals.' This mix shift is critical for defending margins against generic pricing pressure.
Separation Distraction Risk
The company is sprinting toward a H2 2026 separation. While strategically sound, the operational burden is high: naming new CEOs, launching brands, and splitting IT systems. With Q4 showing execution slips (shipping delays), the risk of internal distraction impacting 2026 operations is real.
Latin America Volatility
Latin America remains a source of volatility. CP pricing fell due to market dynamics there, and Seed volumes shifted due to 'early deliveries' moving to Q3 and weather delays pushing others to Q1. The region's unpredictability is smoothing quarterly earnings but making specific periods look erratic.
Other KPIs
Accelerating. Up 69% from the prior year. This demonstrates high quality of earnings and efficient working capital management, crucial for funding the upcoming $610M legal settlement and continued buybacks.
Accelerating. Growth of 14% YoY, with margins expanding 340bps in Seed and 70bps in Crop Protection for the full year. This result highlights that the Q4 weakness was likely an anomaly rather than a trend change.
Stable. Corteva continues to command pricing power in Seed (led by North America) despite a deflationary crop price environment for farmers. This confirms the 'price-for-value' strategy is holding up.
Guidance
Decelerating. The midpoint ($4.1B) implies 7% growth, down from the 14% growth achieved in FY25. This suggests that while cost savings continue, the top-line environment remains challenging.
Decelerating. Midpoint growth of 7%, significantly lower than the 30% surge seen in FY25. The base effect of a strong 2025 makes comparisons tougher.
New negative driver. Management explicitly quantified an $80M hit from incremental global tariffs, which is absorbed into the guidance. This confirms trade headwinds are materializing.
Key Questions
Crop Protection Margin Floor
CP margins collapsed 435bps in Q4 due to pricing and costs. Is Q4 the trough, and how much of the FY26 growth relies on a CP margin rebound versus Seed carrying the load?
Bayer Settlement Cash Impact
Will the $610M cash outflow in Q1 2026 impact the pace of share repurchases in the first half of the year, or will you use balance sheet cash to maintain the buyback cadence?
Volume Shift Visibility
You cited significant volume shifts into Q1 2026. Can you quantify the EBITDA impact of these shifts to help investors understand the 'normalized' Q4 run rate?